Dr. Rapoport Describes Samsca's Mechanism of Action

Video

In Partnership With:

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).

Samsca is a drug used for the treatment of dilutional hyponatremia, a common manifestation of many cancers, including small cell lung cancer.

Samsca is an intelligent drug, Rapoport says, that blocks the vasopressin receptor in the kidneys. By blocking this receptor, the dilute urine can be excreted rather than reabsorbed as fluid in the body, which causes hyponatremia.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD